scholarly article | Q13442814 |
P819 | ADS bibcode | 2001PNAS...98.6342M |
P356 | DOI | 10.1073/PNAS.111031498 |
P932 | PMC publication ID | 33470 |
P698 | PubMed publication ID | 11353837 |
P5875 | ResearchGate publication ID | 11983755 |
P2093 | author name string | Berkhout B | |
Verhoef K | |||
Marzio G | |||
Vink M | |||
P2860 | cites work | Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 |
Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques | Q45751494 | ||
Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus | Q45765427 | ||
Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. | Q45785662 | ||
Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system | Q45887839 | ||
A role for carbohydrates in immune evasion in AIDS | Q47982875 | ||
Viral Dynamics in HIV-1 Infection | Q52038970 | ||
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia | Q57075698 | ||
Dox-dependent SIVmac with tetracycline-inducible promoter in the U3 promoter region | Q73642650 | ||
Is an HIV vaccine possible? | Q77890089 | ||
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1 | Q77901004 | ||
HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter | Q22007982 | ||
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
Importance of the nef gene for maintenance of high virus loads and for development of AIDS | Q29618369 | ||
Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene | Q33196552 | ||
Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort | Q33443744 | ||
Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques | Q33490720 | ||
Strategies used by human immunodeficiency virus that allow persistent viral replication | Q33680601 | ||
Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain. | Q33802066 | ||
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation | Q33814150 | ||
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. | Q33820014 | ||
Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat. | Q33835795 | ||
Biological considerations in the development of a human immunodeficiency virus vaccine | Q33983937 | ||
Multiple biological roles associated with the repeat (R) region of the HIV-1 RNA genome | Q34033118 | ||
Live attenuated HIV vaccines: a proposal for further research and development. | Q34071750 | ||
A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication | Q35879394 | ||
Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1 | Q35884252 | ||
Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus | Q35897786 | ||
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. | Q35905947 | ||
A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. | Q36636854 | ||
A hairpin structure in the R region of the human immunodeficiency virus type 1 RNA genome is instrumental in polyadenylation site selection | Q39548579 | ||
Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains | Q39549272 | ||
A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques | Q39583691 | ||
Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G. | Q39590547 | ||
Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence | Q39871310 | ||
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. | Q39874667 | ||
Can the immune response control HIV infection? | Q40456329 | ||
Mechanisms underlying expression of Tn10 encoded tetracycline resistance | Q40572946 | ||
Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances | Q40846822 | ||
HIV-1 evolves into a nonsyncytium-inducing virus upon prolonged culture in vitro. | Q40920580 | ||
Quantitative dynamics of HIV type 1 expression | Q41237667 | ||
Doxycycline Revisited | Q41532100 | ||
Progress in the Development of an HIV-1 Vaccine | Q45147943 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | vaccine | Q134808 |
doxycycline | Q422442 | ||
P304 | page(s) | 6342-6347 | |
P577 | publication date | 2001-05-15 | |
P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
P1476 | title | In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies | |
P478 | volume | 98 |
Q40280434 | A conditionally replicating HIV-based vector that stably expresses an antiviral shRNA against HIV-1 replication |
Q45606075 | A conditionally replicating virus as a novel approach toward an HIV vaccine |
Q42142952 | A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion |
Q39997896 | A new Houdini act: multiple routes for HIV-1 escape from RNAi-mediated inhibition |
Q37331638 | A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs |
Q34124490 | Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing. |
Q34329754 | Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction |
Q36632210 | Anti-viral opportunities during transcriptional activation of latent HIV in the host chromatin |
Q45888148 | Autoregulatory lentiviral vectors allow multiple cycles of doxycycline-inducible gene expression in human hematopoietic cells in vivo |
Q37589012 | Chromatin dynamics associated with HIV-1 Tat-activated transcription |
Q35193454 | Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine |
Q38486077 | Conditionally replicating HIV and SIV variants |
Q40891549 | Construction of Nef-positive doxycycline-dependent HIV-1 variants using bicistronic expression elements. |
Q36099319 | Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication. |
Q35070255 | Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias |
Q34556271 | Control over HIV-1 replication by an antibiotic; a novel vaccination strategy with a drug-dependent virus |
Q40371694 | Controlling Multicycle Replication of Live-Attenuated HIV-1 Using an Unnatural Genetic Switch |
Q36417492 | Cotranscriptional Chromatin Remodeling by Small RNA Species: An HTLV-1 Perspective |
Q36828170 | Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression |
Q34350633 | Differential requirements for activation of integrated and transiently transfected human T-cell leukemia virus type 1 long terminal repeat |
Q35096745 | EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine |
Q39682784 | Efficient human immunodeficiency virus replication requires a fine-tuned level of transcription |
Q37596642 | Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. |
Q35180176 | Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes |
Q92135927 | Genetic variation and function of the HIV-1 Tat protein |
Q37755873 | HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms |
Q38534476 | HIV-1 latency in actively dividing human T cell lines |
Q21134702 | HTLV-1 Tax Mediated Downregulation of miRNAs Associated with Chromatin Remodeling Factors in T Cells with Stably Integrated Viral Promoter |
Q40589914 | Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition |
Q33235333 | IPRO: an iterative computational protein library redesign and optimization procedure |
Q33755382 | Improved Tet-responsive promoters with minimized background expression |
Q33269863 | Improved single-chain transactivators of the Tet-On gene expression system |
Q40121209 | Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors |
Q42104875 | Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry |
Q33222949 | Laboratory-directed protein evolution |
Q27497985 | Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines |
Q34733983 | Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition |
Q39136662 | Modification of the Tet-On regulatory system prevents the conditional-live HIV-1 variant from losing doxycycline-control |
Q28242232 | Optimization of the Tet-On system for regulated gene expression through viral evolution |
Q36743410 | Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution |
Q37768033 | Possible applications for replicating HIV 1 vectors |
Q36716418 | Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. |
Q46655345 | Retroviral replicating vectors in cancer |
Q38838489 | Selecting the optimal Tet-On system for doxycycline-inducible gene expression in transiently transfected and stably transduced mammalian cells |
Q41923238 | Synthetic biology approach for the development of conditionally replicating HIV-1 vaccine |
Q38842593 | Tet-On Systems For Doxycycline-inducible Gene Expression. |
Q38286131 | The HIV-1 Tat Protein Has a Versatile Role in Activating Viral Transcription |
Q42431758 | The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription |
Q46016251 | The art of survival during viral persistence. |
Q83181178 | The genetic stability of a conditional live HIV-1 variant can be improved by mutations in the Tet-On regulatory system that restrain evolution |
Q45416488 | Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge |
Q33850355 | Vaccination with attenuated simian immunodeficiency virus by DNA inoculation |
Q44755157 | Viral evolution as a tool to improve the tetracycline-regulated gene expression system |
Q31063252 | eCodonOpt: a systematic computational framework for optimizing codon usage in directed evolution experiments |
Q37890571 | miRNA cassettes in viral vectors: Problems and solutions |